neonatal case presentation

Case Presentation: Approach to the Sick Neonate

At the end of this session, learners will be able to understand the process of intervention and diagnosis regarding an unknown neonate patient case.

• Archana Verma, MD

This seminar focuses on emergency medicine and was delivered at the Open Medical Institute in Salzburg, Austria, from November 27 – December 3, 2022.

Content Disclaimer

The Terms of Use and Privacy Policy set forth on the website of The Children’s Hospital of Philadelphia apply to any and all uses of and access to this site and the content found here.

The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.

CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.

To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.

Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.

You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.

The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.

By starting this module, you agree to our Content Disclaimer and Terms of Service.

Course Content

Course Includes

• Course Certificate

CHOP Employee? Log In Here

Username or Email Address

Forgot Password?

Remember Me

An official website of the United States government

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

• Publications
• Account settings
• Advanced Search
• Journal List

Case 1: A newborn in distress

Rebecca levy , md, sharon naymark , md frcpc.

• Author information
• Article notes
• Copyright and License information

Correspondence: Dr Sharon Naymark, Department of Pediatrics, St Joseph’s Health Centre, 30 The Queensway, Toronto, Ontario M6R 1B5. Telephone 416-530-6000, e-mail [email protected]

Accepted 2011 Jun 1.

A newborn boy presented to the emergency room at 24 h of life with respiratory distress and jitteriness.

He was born at term to a G1P0 mother who had an unremarkable pregnancy, protective serologies and no diabetes. She tested negative for group B streptococcus, and had no history of maternal herpes simplex virus infection. She denied smoking, alcohol and recreational drug use during pregnancy. The baby was born at home following an uncomplicated vaginal delivery. At 24 h of life, the baby was still grunting and jittery, and was brought to the emergency department.

In the emergency department, he was in moderate respiratory distress. His respiratory rate was 76 breaths/min, with visible subcostal indrawing and nasal flaring. His heart rate was 150 beats/min, O 2 saturation was 92% on room air and his rectal temperature was 36.8°C. The infant was alert, appeared warm and pink, but demonstrated fine tremor in all four limbs, which was suppressed by holding his limbs firmly. There were no dysmorphic features, fontanelles were flat, and the infant’s cardiorespiratory examination was normal. Neurological examination revealed normal primitive reflexes, but significantly increased tone to all four limbs.

The infant’s bedside glucose level measured 0.34 g/L, which was normalized with a bolus of 10% dextrose in water. Jittery movements and hypertonia persisted despite correction of hypoglycemia. Full septic work-up was performed, and the infant was started on broad-spectrum antibiotics and admitted to the neonatal intensive care unit.

Additional information from the mother provided the diagnosis.

CASE 1 DIAGNOSIS: POOR NEONATAL ADAPTATION SYNDROME

On admission to the neonatal intensive care unit, the infant was stabilized using continuous positive airway pressure. The infant’s cultures were negative at 48 h; therefore, antibiotics were discontinued. His respiratory distress, jitteriness and hypertonia gradually resolved, and the infant was discharged home after three days in hospital.

The infant’s mother later reported that she was taking citalopram (40 mg daily) throughout the pregnancy for depression. There was no other illicit or prescribed drug exposure. At six months of age, the infant is developing appropriately.

After a negative work-up and, with relatively rapid improvement with supportive care, the infant was diagnosed with poor neonatal adaptation syndrome – a group of maladaptive symptoms associated with maternal exposure to selective serotonin reuptake inhibitors (SSRIs) in late pregnancy. Also known as neonatal behaviour syndrome, this condition is comprised of a spectrum of symptoms including irritability, respiratory distress, jitteriness, hypotonia or hypertonia, hypoglycemia, feeding difficulties, seizures, hypothermia, sleep disturbance and jaundice ( 1 , 2 ).

Depression is common among pregnant women, with an estimated prevalence of 7% to 16%. Adverse perinatal effects associated with untreated or poorly managed depression include prematurity, low birth weight, growth retardation and increased risk of fetal death. Maternal-infant bonding and postpartum infant care may also be adversely affected ( 2 , 3 ).

Poor neonatal adaptation syndrome has been associated with a variety of SSRIs and serotonin noradrenaline reuptake inhibitors. The mechanism is not well understood; it has been proposed by some to be a discontinuation reaction similar to that seen in adults ( 2 ). However, a form of toxicity or serotonergic syndrome as the causative mechanism cannot be ruled out. Moreover, depression itself has been shown to adversely impact the neonate and, therefore, the mechanism is likely to be multifactorial ( 1 ).

Management of poor neonatal adaptation syndrome primarily consists of supportive care. Identification of at-risk infants and education of parents and health professionals is critical to effective counselling and early management. Admission may be required for stabilization; symptoms generally self-resolve within a few days to a maximum of four weeks. More severe presentations of the syndrome are relatively rare (approximately 0.3%), and no reported deaths have been attributed to antenatal SSRI exposure ( 1 ).

Apart from poor neonatal adaptation, the data describing other potential adverse fetal effects associated with in utero SSRI exposure are conflicting. While many studies have shown SSRIs to be free of teratogenic effects, some studies ( 4 ) have reported a small elevation in the risk of congenital defects, including septal heart defects and omphalocele. When implicated, the absolute risk of congenital defects was small ( 4 ). Paroxetine has been shown, in a limited number of studies, to increase the risk of congenital heart defects 1.5-fold to 2-fold, but the possibility of detection bias related to increased rates of both fetal ultrasound and infant echocardiography has been suggested ( 5 ). Regardless, paroxetine’s Food and Drug Administration pregnancy category was changed from C (risk cannot be ruled out) to D (positive evidence of risk) as a result of this potential risk. Guidelines from the American Congress of Obstetrics and Gynecology (Washington, USA) state that paroxetine use in pregnant women should be avoided, if possible, and fetal echocardiography should be considered for women who are exposed to paroxetine in early pregnancy (level B) ( 3 ).

Finally, neurodevelopmental outcomes of children exposed to SSRIs in utero have been examined in a limited number of studies. While these studies demonstrated normal neurodevelopment through childhood, additional investigation and long-term follow-up are warranted to further elucidate the long-term sequelae of in utero SSRI exposure.

Considerable debate exists regarding the specific effects of newer SSRIs and serotonin noradrenaline reuptake inhibitors, and further investigation is required to characterize these effects.

Given the prevalence of depression in pregnant women, the well-established adverse effects of untreated depression on maternal and fetal health, and the conflicting data surrounding safety of SSRIs in pregnancy, clinicians are presented with a considerable challenge in counselling pregnant women with depression. The potential risks associated with SSRI use in pregnancy must be balanced with the risks associated with depression to both mother and fetus, as well as the risk of depression relapse if treatment is discontinued. Motherisk ( www.motherisk.org ) – a valuable Canadian resource for safety issues surrounding pregnancy – currently recommends that in addition to weighing the risks and benefits of discontinuing antidepressant medication during pregnancy, infants born to mothers taking SSRIs during late pregnancy be closely monitored for longer than the typical 24 h to 48 h after birth.

CLINICAL PEARLS

When presented with a neonate in distress, it is critical to obtain a detailed maternal medication history.

Poor neonatal adaptation is a syndrome of maladaptive symptoms in neonates exposed to SSRIs in the third trimester of pregnancy; it is generally mild and self-limited, and primarily requires supportive management.

Identification of at-risk infants and the education of parents and health professionals are critical to effective counselling and early management of poor neonatal adaptation syndrome.

• 1. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA. 2005;293:2372–83. doi: 10.1001/jama.293.19.2372. [ DOI ] [ PubMed ] [ Google Scholar ]
• 2. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193:2004–9. doi: 10.1016/j.ajog.2005.05.012. [ DOI ] [ PubMed ] [ Google Scholar ]
• 3. ACOG Practice Bulletin Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111:1001–12. [ Google Scholar ]
• 4. Pederson LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ. 2009;339:b3569. doi: 10.1136/bmj.b3569. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
• 5. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29:918–26. doi: 10.1016/j.clinthera.2007.05.003. [ DOI ] [ PubMed ] [ Google Scholar ]
• View on publisher site
• PDF (475.6 KB)
• Collections

Similar articles

Cited by other articles, links to ncbi databases.

• Download .nbib .nbib
• Format: AMA APA MLA NLM

Add to Collections

The Journal of Neonatal-Perinatal Medicine

Search form.

• Browse Articles
• Congenital depressed fracture of the skull in a neonate
• An unusual cause of worsening respiratory distress in an infant with Pentalogy of Cantrell
• Case presentation: Tuberculosis in a newborn infant
• Hepatoblastoma: A rare cause of non-immune hydrops in a preterm infant
• Primary pulmonary lymphangiectasia in an infant with Trisomy 21
• Spontaneous perforation of Meckel’s diverticulum in an extremely premature baby
• Staphylococcus aureus sepsis inducing severe hemolysis in G6PD-deficient preterm infant causing severe jaundice and kernicterus
• Subdural total parenteral nutrition collection: A complication of a peripheral scalp intravenous catheter in a neonate
• Tracheal agenesis: Respiratory distress, aphonia and emergency airway management
• Plastic bronchitis: An unusual cause of airway obstruction in the neonatal intensive care unit
• Heparin therapy: A potential risk factor for fractures in preterm neonates
• Perinatal dengue infection: Two new cases
• A case of neonatal pulmonary Aspergillosis successfully treated with micafungin

Browse Clinical Case

Transcutaneous electromyography as a tool to assess recovery of hemidiaphragmatic paresis: a case report, multiple vascular malformations in a newborn, a rare case of hepatic sinusoidal occlusive syndrome in a premature neonate with trisomy 21, prognostic dilemmas for sids in idiopathic fetal right atrium dilatation: case report and review literature, a case series of fetal lymphatic malformations and a review of the literature, perinatal outcome in prenatally diagnosed cardiac rhabdomyoma case series, acquired hydrocephalus following hypoxic ischemic encephalopathy without intraventricular hemorrhage: a case report.